Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy

Next Previous
X
Search
Trial Profile

Phase I Study of Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epacadostat (Primary) ; Sirolimus (Primary)
  • Indications Colorectal cancer; Gallbladder cancer; Non-small cell lung cancer; Oesophageal cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 06 Jun 2023 Results of safety and tolerability of SE combination in patients with advanced solid tumors and performed PK studies presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 28 Apr 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2025.
    • 28 Apr 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top